Venlafaxine in depressed geriatric outpatients: An open-label clinical study

A. Khan, R. Rudolph, B. Baumel, J. Ferguson, P. Ryan, R. Shrivastava

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


A 12-month open-label clinical trial was conducted to evaluate patient acceptance and safety of venlafaxine, a novel antidepressant, in ambulatory geriatric depressed patients. The sample consisted of 58 depressed patients aged 65 years end older who needed long-term antidepressant treatment. The setting was multiple study sites in California, Florida, New York, Utah, and Washington. All patients took venlafaxine; 52 qualified for the intent-to- treat analysis, and 24 completed 12 months of treatment. Repeated-measures analysis of variance within subjects showed significant improvements in Clinical Global impressions severity and improvement, Modified Symptom Checklist, and Quality of Life Questionnaire scores. One patient developed a rash that was judged to be a serious drug-related side effect. The most common side effects were headache (n=25), nausea (n=21), insomnia (n=18), dry mouth (n=18), and sweating (n=18). The results demonstrate the safety and patient acceptance of venlafaxine in depressed geriatric outpatients for acute and maintenance treatment.

Original languageEnglish (US)
Pages (from-to)753-758
Number of pages6
JournalPsychopharmacology bulletin
Issue number4
StatePublished - 1995
Externally publishedYes


  • antidepressants
  • depression
  • geriatric
  • venlafaxine

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Venlafaxine in depressed geriatric outpatients: An open-label clinical study'. Together they form a unique fingerprint.

Cite this